Although major advances have recently been made in pharmacological research, unfortunately, tissue plasminogen activator (tPA) is the only FDA-approved drug for the clinical treatment of ischemic stroke to date, and its clinical use is limited by the narrow time window and the risk for hemorrhage. The gene discussed is PLAT; the disease is ischemic stroke.